1.1 Articolo in rivista

1.1 Articolo in rivista: [26843] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 2.841 a 2.860 di 26.843

Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction

2017-01-01 Cattaneo, D; Rizzardini, G; Gervasoni, C

Pharmacokinetics of mycophenolate sodium and comparison with the mofetil transplant recipients formulation in stable kidney

2007-01-01 Cattaneo, D; Cortinovis, Monica; Baldelli, Sara; Bitto, Alessandra; Gotti, Eliana; Remuzzi, Giuseppe; Perico, Norberto

Application Of Quality By Design Approach To Bioanalysis: Development Of A Method For Elvitegravir Quantification In Human Plasma

2017-01-01 Baldelli, S; Marrubini, G; Cattaneo, D; Clementi, E; Cerea, M.

Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients

2015-01-01 Gervasoni, C.; Riva, A.; Rizzardini, G.; Clementi, E.; Galli, M.; Cattaneo, D.

Optimizing immunosuppressive drug dosing in pediatric renal transplantation

2012-01-01 Cattaneo, D; Vinks Alexander, A.

Immune deficiency is a risk factor for severe COVID-19 in people living with HIV

2021-01-01 Hoffmann, C; Casado, Jl; Härter, G; Vizcarra, P; Moreno, A; Cattaneo, D; Meraviglia, P; Spinner, Cd; Schabaz, F; Grunwald, S; Gervasoni, C.

Potential association between chia seeds use and low atazanavir trough concentrations in an HIV-infected patient

2023-01-01 Cattaneo, D; Pagano, S; Beltrami, M; Micheli, V; Gervasoni, C.

Why Product Information Should not be Set in Stone: Lessons from a Decade of Linezolid Therapeutic Drug Monitoring: An Opinion Paper

2023-01-01 Marriott, Dje; Cattaneo, D

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

2017-01-01 Cattaneo, D; Minisci, D; Cozzi, V; Riva, A; Meraviglia, P; Clementi, E; Galli, M; Gervasoni, C.

Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients

2001-01-01 Caruso, R; Perico, N; Cattaneo, D; Piccinini, G; Bonazzola, S; Remuzzi, G; Gaspari, F

Generic cyclosporine formulations: more open questions than answers

2005-01-01 Cattaneo, D; Perico, N; Remuzzi, G

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

2007-01-01 Ripamonti, Diego; Cattaneo, D; Maggiolo, Franco; Airoldi, Monica; Frigerio, Luigi; Bertuletti, Pierangelo; Ruggeri, Maurizio; Suter, Fredy

Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples

2022-01-01 Baldelli, S; Cerea, M; Mangioni, D; Alagna, L; Muscatello, A; Bandera, A; Cattaneo, D

Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype

2014-01-01 Rusconi, S.; Gagliardini, R.; Falvella, F. S.; Cattaneo, D.; Di Cristo, V.; De Luca, A.; Fabbiani, M.; Clementi, E.; Galli, M.; Di Giambenedetto, S.

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients

2016-01-01 Ferretti, F; Bigoloni, A; Passeri, L; Galli, L; Longo, V; Gerevini, S; Spagnuolo, V; Gisslen, M; Zetterberg, H; Fuchs, D; Cattaneo, D; Caramatti, G; Lazzarin, A; Cinque, P; Castagna, A.

Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?

2020-01-01 Baldelli, S; Montrasio, C; Cheli, S; Viganò, O; Bini, T; Egidi, M; Cattaneo, D

Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

2021-01-01 Maggiore, U; Palmisano, A; Buti, S; Claire Giudice, G; Cattaneo, D; Giuliani, N; Fiaccadori, E; Gandolfini, I; Cravedi, P.

Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study

2022-01-01 Pozzi, M; Zanotta, N; Epifanio, R; Baldelli, S; Cattaneo, D; Clementi, E; Zucca, C

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

2023-01-01 Cheli, S; Savino, D; De Silvestri, A; Norsa, L; Sansotta, N; Penagini, F; Dilillo D, ; Panceri, R; Cattaneo, D; Clementi, E; Zuin, G

Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience

2020-01-01 Baldelli, S.; Cheli, S.; Montrasio, C.; Cattaneo, D.; Clementi, E.

Titolo	Data di pubblicazione	Autore(i)
Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction	1-gen-2017	Cattaneo, D; Rizzardini, G; Gervasoni, C
Pharmacokinetics of mycophenolate sodium and comparison with the mofetil transplant recipients formulation in stable kidney	1-gen-2007	Cattaneo, D; Cortinovis, Monica; Baldelli, Sara; Bitto, Alessandra; Gotti, Eliana; Remuzzi, Giuseppe; Perico, Norberto
Application Of Quality By Design Approach To Bioanalysis: Development Of A Method For Elvitegravir Quantification In Human Plasma	1-gen-2017	Baldelli, S; Marrubini, G; Cattaneo, D; Clementi, E; Cerea, M.
Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients	1-gen-2015	Gervasoni, C.; Riva, A.; Rizzardini, G.; Clementi, E.; Galli, M.; Cattaneo, D.
Optimizing immunosuppressive drug dosing in pediatric renal transplantation	1-gen-2012	Cattaneo, D; Vinks Alexander, A.
Immune deficiency is a risk factor for severe COVID-19 in people living with HIV	1-gen-2021	Hoffmann, C; Casado, Jl; Härter, G; Vizcarra, P; Moreno, A; Cattaneo, D; Meraviglia, P; Spinner, Cd; Schabaz, F; Grunwald, S; Gervasoni, C.
Potential association between chia seeds use and low atazanavir trough concentrations in an HIV-infected patient	1-gen-2023	Cattaneo, D; Pagano, S; Beltrami, M; Micheli, V; Gervasoni, C.
Why Product Information Should not be Set in Stone: Lessons from a Decade of Linezolid Therapeutic Drug Monitoring: An Opinion Paper	1-gen-2023	Marriott, Dje; Cattaneo, D
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?	1-gen-2017	Cattaneo, D; Minisci, D; Cozzi, V; Riva, A; Meraviglia, P; Clementi, E; Galli, M; Gervasoni, C.
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients	1-gen-2001	Caruso, R; Perico, N; Cattaneo, D; Piccinini, G; Bonazzola, S; Remuzzi, G; Gaspari, F
Generic cyclosporine formulations: more open questions than answers	1-gen-2005	Cattaneo, D; Perico, N; Remuzzi, G
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer	1-gen-2007	Ripamonti, Diego; Cattaneo, D; Maggiolo, Franco; Airoldi, Monica; Frigerio, Luigi; Bertuletti, Pierangelo; Ruggeri, Maurizio; Suter, Fredy
Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples	1-gen-2022	Baldelli, S; Cerea, M; Mangioni, D; Alagna, L; Muscatello, A; Bandera, A; Cattaneo, D
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype	1-gen-2014	Rusconi, S.; Gagliardini, R.; Falvella, F. S.; Cattaneo, D.; Di Cristo, V.; De Luca, A.; Fabbiani, M.; Clementi, E.; Galli, M.; Di Giambenedetto, S.
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients	1-gen-2016	Ferretti, F; Bigoloni, A; Passeri, L; Galli, L; Longo, V; Gerevini, S; Spagnuolo, V; Gisslen, M; Zetterberg, H; Fuchs, D; Cattaneo, D; Caramatti, G; Lazzarin, A; Cinque, P; Castagna, A.
Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?	1-gen-2020	Baldelli, S; Montrasio, C; Cheli, S; Viganò, O; Bini, T; Egidi, M; Cattaneo, D
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?	1-gen-2021	Maggiore, U; Palmisano, A; Buti, S; Claire Giudice, G; Cattaneo, D; Giuliani, N; Fiaccadori, E; Gandolfini, I; Cravedi, P.
Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study	1-gen-2022	Pozzi, M; Zanotta, N; Epifanio, R; Baldelli, S; Cattaneo, D; Clementi, E; Zucca, C
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study	1-gen-2023	Cheli, S; Savino, D; De Silvestri, A; Norsa, L; Sansotta, N; Penagini, F; Dilillo D, ; Panceri, R; Cattaneo, D; Clementi, E; Zuin, G
Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience	1-gen-2020	Baldelli, S.; Cheli, S.; Montrasio, C.; Cattaneo, D.; Clementi, E.

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 2.841 a 2.860 di 26.843

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext24590
reserved1362
open891